[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 4964 Introduced in Senate (IS)]

<DOC>






118th CONGRESS
  2d Session
                                S. 4964

    To provide for a comprehensive Federal response to Long COVID, 
including research, education, and support for affected individuals, to 
  direct the National Institutes of Health to establish a Long COVID 
               research program, and for other purposes.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             August 1, 2024

  Mr. Sanders (for himself, Ms. Duckworth, Mr. Kaine, Mr. Markey, Ms. 
  Smith, and Mr. Welch) introduced the following bill; which was read 
 twice and referred to the Committee on Health, Education, Labor, and 
                                Pensions

_______________________________________________________________________

                                 A BILL


 
    To provide for a comprehensive Federal response to Long COVID, 
including research, education, and support for affected individuals, to 
  direct the National Institutes of Health to establish a Long COVID 
               research program, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Long COVID Research Moonshot Act''.

                TITLE I--LONG COVID BIOMEDICAL RESEARCH

SEC. 101. ESTABLISHMENT OF LONG COVID RESEARCH PROGRAM.

    Title IV of the Public Health Service Act (42 U.S.C. 281 et seq.) 
is amended by adding at the end the following:

                      PART K--LONG COVID PROGRAMS

    

``SEC. 499B. ESTABLISHMENT OF LONG COVID RESEARCH PROGRAM.

    ``(a) In General.--There is established within the Office of the 
Director of the National Institutes of Health a research program, to be 
known as the Long COVID Research Program (referred to in this part as 
the `Program'), for purposes of expediting research to identify new 
ways to prevent, detect, manage, and treat symptoms associated with 
Long COVID.
    ``(b) Director.--
            ``(1) Appointment.--
                    ``(A) In general.--The Program shall be headed by a 
                Director, appointed by the Secretary, in consultation 
                with the Director of NIH, who has--
                            ``(i) experience managing clinical or 
                        research programs focused on pathogenic 
                        mechanisms and biological pathways related to 
                        Long COVID; and
                            ``(ii) demonstrated commitment to 
                        addressing Long COVID and other infection-
                        associated chronic conditions, such as myalgic 
                        encephalomyelitis/chronic fatigue syndrome, 
                        postural orthostatic tachycardia syndrome, and 
                        post-treatment Lyme disease syndrome/persistent 
                        Lyme disease.
                    ``(B) Consultation.--In appointing the Director 
                under subparagraph (A), the Secretary shall consult 
                with independent, patient-led organizations or advocacy 
                groups representing Long COVID patients and their 
                families.
            ``(2) Responsibilities.--The Director of the Program 
        shall--
                    ``(A) act as the primary Federal official with 
                responsibility for coordinating all Long COVID research 
                conducted or supported by the National Institutes of 
                Health;
                    ``(B) represent the National Institutes of Health 
                Long COVID Research Program at all relevant Executive 
                branch task force meetings and committees; and
                    ``(C) maintain communication with all relevant 
                Federal departments and agencies to ensure the timely 
                transmission of information concerning advances in Long 
                COVID research and the clinical treatment of Long COVID 
                and other infection-associated chronic conditions 
                between such departments and agencies, and for 
                dissemination to affected communities and health care 
                providers.
    ``(c) Activities.--The Program shall--
            ``(1) investigate the etiology, pathophysiology, risk 
        factors, and pathology of Long COVID in adults and children;
            ``(2) explore the best ways to prevent, detect, monitor, 
        manage, and treat Long COVID in adults and children;
            ``(3) contribute knowledge to the understanding, 
        prevention, mitigation, management, and treatment of Long 
        COVID;
            ``(4) develop and facilitate programs on Long COVID, within 
        the National Institutes of Health and in other settings;
            ``(5) conduct comparative research to understand the 
        similarities and differences between Long COVID and other 
        infection-associated chronic conditions with similar 
        phenotypes, such as myalgic encephalomyelitis/chronic fatigue 
        syndrome, postural orthostatic tachycardia syndrome, and post-
        treatment Lyme disease syndrome/persistent Lyme disease, and 
        how activities funded by the Program could improve 
        understanding of such other conditions; and
            ``(6) conduct comparative research to understand the 
        similarities and differences between Long COVID and severe, 
        long-term effects from COVID-19 vaccinations.
    ``(d) Duties.--
            ``(1) Interagency coordination of long covid activities.--
        The Director of the Program shall coordinate with the national 
        research institutes and national centers, as appropriate, on 
        Long COVID research. In carrying out this paragraph, the 
        Director of the Program shall evaluate the Long COVID 
        activities of each such institute or center and shall provide 
        for the periodic reevaluation of such activities.
            ``(2) Consultation.--The Director of the Program shall 
        carry out all duties, including the development of the research 
        plan under section 499B-1 in consultation with the heads of the 
        national research institutes and national centers, with the 
        advisory councils of such institutes and centers, and with the 
        Long COVID Research Program Advisory Board established under 
        section 499B-4.
    ``(e) Non-Duplication of Effort.--The Director shall ensure that 
activities carried out under this section do not unnecessarily 
duplicate the efforts of other Federal departments or agencies.

``SEC. 499B-1. LONG COVID RESEARCH PLAN.

    ``(a) In General.--Not later than 1 year after the date of 
enactment of the Long COVID Research Moonshot Act, the Director of the 
Program established under section 499B shall develop and make public a 
comprehensive research plan for the conduct and support of all Long 
COVID research activities of the national research institutes and 
national centers. The Director of the Program shall update such plan 
annually.
    ``(b) Contents.--The research plan developed under subsection (a) 
shall--
            ``(1) identify current Long COVID research conducted or 
        supported by the national research institutes and national 
        centers, opportunities and needs for additional research, 
        including among patients who face the highest disease burden 
        and pediatric patients, and priorities for such research;
            ``(2) evaluate the progress of Long COVID research against 
        strategic priorities, goals, and objectives, identified in 
        previous versions of the research plan;
            ``(3) make recommendations for the coordination of such 
        research conducted or supported by the National Institutes of 
        Health and other agencies of the Federal Government; and
            ``(4) include goals and objectives of the Program for 
        conducting, supporting, and coordinating Long COVID research.
    ``(c) Requirements.--In developing the research plan under 
subsection (a), the Director of the Program shall--
            ``(1) ensure that the plan establishes priorities among 
        Long COVID research that the Program is authorized to carry 
        out;
            ``(2) ensure that the plan establishes objectives regarding 
        such research and describes the means for achieving the 
        objectives;
            ``(3) ensure that all amounts appropriated for such 
        research under section 499B-6 are expended in accordance with 
        the plan;
            ``(4) review the plan not less frequently than annually, 
        and revise the plan as appropriate to prioritize funding and 
        research relative to scientific urgency;
            ``(5) ensure that the plan serves as a broad, binding 
        statement of policies regarding Long COVID research of the 
        National Institutes of Health, but does not affect the 
        responsibility of any of the national research institutes or 
        centers with respect to the programs or projects of such 
        institutes and centers; and
            ``(6) annually prepare and submit to the Director of NIH 
        for review and transmittal by the Director of NIH to the 
        President and to Congress a budget estimate for carrying out 
        the plan for the upcoming fiscal year.
    ``(d) Consultation.--In developing, implementing, reviewing, and 
prioritizing elements of the research plan under this section, the 
Director of the Program shall consult, as appropriate with--
            ``(1) representatives of other Federal agencies involved in 
        Long COVID research, including the Centers for Disease Control 
        and Prevention, the Agency for Healthcare Research and Quality, 
        and the Administration for Community Living;
            ``(2) the Long COVID Research Advisory Board established 
        under section 499B-4;
            ``(3) the Office of Long COVID Research and Practice of the 
        Department of Health and Human Services;
            ``(4) leading scientific experts on Long COVID; and
            ``(5) independent, patient-led organizations or advocacy 
        groups representing patients with Long COVID and other 
        infection-associated chronic conditions with similar 
        phenotypes, and the families of such patients.
    ``(e) Report.--The Director of the Program shall submit the 
research plan developed under subsection (a), and updates to such plan, 
to--
            ``(1) the Committee on Health, Education, Labor, and 
        Pensions of the Senate;
            ``(2) the Committee on Energy and Commerce of the House of 
        Representatives;
            ``(3) the Secretary;
            ``(4) the Office of Long COVID Research and Practice of the 
        Department of Health and Human Services; and
            ``(5) the Director of NIH, who shall post the plan, and 
        updates to the plan, on the website of the National Institutes 
        of Health.

``SEC. 499B-2. EXPEDITED LONG COVID RESEARCH.

    ``(a) In General.--The Director of NIH shall establish a process to 
expedite the award of grants, contracts, and cooperative agreements for 
research projects conducted or supported by the National Institutes of 
Health and relating to Long COVID.
    ``(b) Requirements for Making External Funding Available.--With 
respect to programs of grants, contracts, and cooperative agreements 
described in subsection (a), the Director of NIH shall--
            ``(1) make publicly available the deadlines for submitting 
        applications for such programs, and ensure that such deadlines 
        provide applicants with sufficient time from the date of the 
        announcement for such grant, contract, and cooperative 
        agreement to submit an application;
            ``(2) ensure that applicants receive a final decision on 
        their applications within 120 days of submission; and
            ``(3) with respect to applications that are denied, provide 
        a written explanation to the applicant on the reasons for the 
        denial.
    ``(c) Evaluation of Grant Applications.--In making a determination 
to award a grant, contract, and cooperative agreement for research 
projects described in subsection (a), the Director of NIH shall--
            ``(1) give priority to research that--
                    ``(A) tests the outcomes of existing drug and 
                device interventions in patients with Long COVID;
                    ``(B) focuses on identifying interventions for 
                pediatric patients with Long COVID;
                    ``(C) aids in the development of new interventions 
                that have evidence to suggest effectiveness in treating 
                or curing Long COVID; or
                    ``(D) includes institutions that represent, or have 
                a successful track record of providing equitable care 
                or services to, historically underserved communities;
            ``(2) consider research that has the ability to begin 
        interventions in a timely manner;
            ``(3) consider research that uses decentralized trials or 
        remote monitoring techniques for data collection; and
            ``(4) consider research that includes patients with other 
        infection-associated chronic conditions with similar 
        phenotypes, such as myalgic encephalomyelitis/chronic fatigue 
        syndrome, postural orthostatic tachycardia syndrome, and post-
        treatment Lyme disease syndrome/persistent Lyme disease.
    ``(d) Reasonable Pricing.--In awarding contracts, grants, and 
cooperative agreements for research projects described in subsection 
(a) that relates to the development of a drug or device for the 
potential treatment or management of Long COVID, or identifying a new 
indication or use specific to the treatment or management of Long COVID 
in a drug or device that is already approved or cleared by the Food and 
Drug Administration, the Director of NIH shall include terms and 
conditions requiring that the price of such a drug or device for 
purposes of procurement by the Federal Government or if sold on the 
commercial market, whether procured from, or sold by, the recipient of 
such Federal award or another person--
            ``(1) is fair and reasonable, taking into account--
                    ``(A) the value of the drug and device to the 
                public health, including the impact of the price on 
                access to the drug or device;
                    ``(B) the costs incurred by the Federal Government 
                in research and development of the drug or device;
                    ``(C) the costs incurred by the recipient of the 
                award in research and development of the drug or 
                device, and the costs of manufacturing such drug or 
                device;
                    ``(D) whether the drug or device provided a 
                significant improvement in health outcomes, compared to 
                other therapies available at the time of its approval 
                or authorization;
                    ``(E) the cumulative expected global revenues 
                generated by the drug or device; and
                    ``(F) other factors, as the Secretary determines 
                appropriate; and
            ``(2) does not exceed the lowest price charged for such 
        drug or device, among Canada, France, Germany, Italy, Japan, 
        and the United Kingdom.
    ``(e) Consultation.--In making a determination to award a grant, 
contract, or cooperative agreement for research projects relating to 
Long COVID, the Director of NIH shall consult with the Long COVID 
Research Advisory Board. Members of the Long COVID Research Advisory 
Board shall provide a recommendation on any final funding decisions. If 
the Director of NIH makes a decision that is different than the 
recommendation, the Director of NIH shall provide a written 
justification for the decision within 5 days.

``SEC. 499B-3. SCIENTIFIC REVIEW GROUP.

    ``(a) In General.--In order to ensure high quality, rigorous 
scientific review of applications for grants, contracts, and 
cooperative agreements described in section 499B-2(a), consistent with 
section 492, the Director of NIH shall establish a scientific review 
group on Long COVID and other infection-associated chronic conditions, 
and shall convene a group of leading scientific experts to serve on 
such group, for terms of up to 5 years.
    ``(b) Duties.--The scientific research group shall conduct an 
initial review of applications for grants, contracts, and other 
cooperative agreements described in section 499B-2(a), and submit a 
funding recommendation to the Director of NIH for final determination.

``SEC. 499B-4. LONG COVID RESEARCH PROGRAM ADVISORY BOARD.

    ``(a) In General.--The Director of NIH shall establish the Long 
COVID Research Program Advisory Board (referred to in this section as 
the `Advisory Board').
    ``(b) Membership.--
            ``(1) In general.--The Advisory Board shall be comprised of 
        18 members, including appointed members and nonvoting ex 
        officio members, as follows:
                    ``(A) The Secretary shall conduct a nomination 
                process that allows for public input on nominees. The 
                Secretary shall appoint nominated individuals, giving 
                particular consideration to individuals from 
                backgrounds that represent the diversity of the Long 
                COVID population, with an emphasis on patients who face 
                the highest disease burden. Individuals so appointed 
                shall include the following:
                            ``(i) 10 members who are scientists, 
                        physicians, and other health care 
                        professionals, who are not officers or 
                        employees of the Federal Government, and who 
                        have primary expertise in Long COVID and other 
                        infection-associated chronic conditions, with 
                        consideration given to such individuals with 
                        expertise in pediatric populations.
                            ``(ii) 5 members who live with Long COVID.
                            ``(iii) 1 member who is a caregiver to an 
                        individual with Long COVID.
                            ``(iv) 2 members who are employed by the 
                        National Institutes of Health and have 
                        expertise in Long COVID research.
                    ``(B) The following shall be ex officio members of 
                the Advisory Board:
                            ``(i) A representative of the Long COVID 
                        Research Program established under section 499.
                            ``(ii) A representative of the National 
                        Institutes of Health.
                            ``(iii) A representative of the National 
                        Institutes of Neurological Disorders and 
                        Stroke.
                            ``(iv) A representative of the National 
                        Heart, Lung, and Blood Institute.
                            ``(v) A representative of the National 
                        Institute of Allergy and Infectious Diseases.
                            ``(vi) A representative of the Office of 
                        the Assistant Secretary for Health.
                            ``(vii) A representative of the Centers for 
                        Disease Control and Prevention.
                            ``(viii) A representative of the 
                        Administration for Community Living.
                            ``(ix) A representative of the Agency for 
                        Healthcare Research and Quality.
                            ``(x) Representatives of any other agency 
                        or office of the Department of Health and Human 
                        Services that the Secretary determines 
                        appropriate for the Advisory Board to carry out 
                        its function.
            ``(2) Engagement with organizations.--In appointing 
        individuals to the Advisory Board, the Secretary shall engage 
        with leading scientific experts on Long COVID and independent, 
        patient-led organizations of advocacy groups representing Long 
        COVID patients.
    ``(c) Compensation.--Ex officio members of the Advisory Board who 
are officers or employees of the Federal Government shall not receive 
any compensation for service on the Advisory Board. Non-Federal members 
of the Advisory Board may receive, for each day (including travel time) 
they are engaged in the performance of the functions of the advisory 
committee, compensation at rates not to exceed the daily equivalent to 
the annual rate of basic pay for level III of the Executive Schedule 
under section 5314 of title 5, United States Code.
    ``(d) Terms.--The term of office of an appointed member of the 
Advisory Board is 5 years. Any member appointed to fill a vacancy for 
an unexpired term shall be appointed for the remainder of such term. A 
member may serve after the expiration of the member's term until a 
successor has taken office. If a vacancy occurs in the Advisory Board, 
the Secretary shall make an appointment to fill the vacancy not later 
than 60 days from the date the vacancy occurred.
    ``(e) Chair.--The members of the Advisory Board shall select a 
chair from among the appointed members. The term of the Office of Chair 
shall be 2 years.
    ``(f) Meetings.--
            ``(1) In general.--The Advisory Board shall meet at the 
        call of the chairman or upon request of the Director of the 
        Program established under section 499B, but not less often than 
        monthly in the first year after establishment, then not less 
        often than 6 times a year for each subsequent year. The 
        meetings of the Advisory Board may be held virtually.
            ``(2) Purpose.--Of the meetings held, one or more shall be 
        held to address research priorities of the National Institutes 
        of Health relating to Long COVID.
            ``(3) Publication of summary.--For each meeting held, the 
        Director of NIH shall post on the website of the National 
        Institutes of Health a summary of the proceedings.
    ``(g) Duties.--The Advisory Board shall, subject to the direction 
and supervision of the Director of NIH--
            ``(1) review, approve, and evaluate the implementation of 
        the research plan issued under section 499B-1, and advise in 
        updating the plan;
            ``(2) provide guidance to the Director of the Program 
        established under section 499B with respect to appropriate 
        research activities to be undertaken regarding the clinical 
        treatment of Long COVID, which may include--
                    ``(A) research on interventions for preventing, 
                treating, and understanding the mechanisms of Long 
                COVID;
                    ``(B) research on the effectiveness of treating 
                Long COVID with drugs that are not yet approved by the 
                Food and Drug Administration for the treatment of Long 
                COVID;
                    ``(C) reviewing ongoing publicly- and privately-
                supported research on treatments for Long COVID;
                    ``(D) issue and make available to health care 
                professionals and the public reports describing and 
                evaluating research described in subparagraphs (A), 
                (B), and (C); and
                    ``(E) convene accessible meetings for the purpose 
                of determining the recommendations which may inform 
                development of clinical guidelines by health care 
                provider organizations; and
            ``(3) engage in other necessary activities to contribute to 
        the National Institutes of Health's overall research priorities 
        related to Long COVID, and ensure accountability, transparency, 
        and communication of results of the Program established under 
        section 499B.''.

``SEC. 499B-5. DATA SYSTEM AND CLEARINGHOUSE ON RESEARCH INFORMATION.

    ``(a) Data System.--
            ``(1) In general.--The Director of the National Institutes 
        of Health, in consultation with the Director of the Program 
        established under section 499B and the Director of the National 
        Library of Medicine shall establish, maintain, and operate a 
        data system for the collection, storage, analysis, retrieval, 
        and timely dissemination of primary data regarding research on 
        Long COVID that is conducted or supported by the Program. 
        Information from the data system shall be available through 
        information systems available to health care professionals and 
        providers, researchers, and members of the public.
            ``(2) Registry.--
                    ``(A) In general.--The data system established 
                under paragraph (1) shall include a registry of 
                clinical trials of experimental treatments that have 
                been developed for research on Long COVID. Such 
                registry shall include information on patient 
                eligibility criteria, including the definition of Long 
                COVID, and, as applicable, demographic information, 
                including sex, age, disability status, ethnicity, and 
                race, and the location of the trial site or sites.
                    ``(B) Submission of information.--Principal 
                investigators of trials described in subparagraph (A) 
                shall provide such information to the registry not 
                later than 30 days after public announcement of the 
                clinical trial. Once a trial has been completed, the 
                principal investigator shall provide the registry with 
                information pertaining to the results, including 
                potential toxicities or adverse effects associated with 
                the experimental treatment or treatments evaluated.
                    ``(C) Public availability.--The registry described 
                in this paragraph shall be made available to 
                researchers and the general public, in a machine-
                readable format.
    ``(b) Clearinghouse.--The Director of NIH, in consultation with the 
Director of the Program and with the National Library of Medicine, 
shall establish, maintain, and operate a program to provide information 
on research and prevention activities of the national research 
institutes that relate to research on Long COVID.

``SEC. 499B-6. APPROPRIATIONS.

    ``For purposes of carrying out this part, there are appropriated, 
out of amounts in the Treasury not otherwise appropriated, 
$1,000,000,000 for each of fiscal years 2025 through 2034, to remain 
available until expended.''.

 TITLE II--PUBLIC HEALTH RESEARCH, SURVEILLANCE AND RELATED ACTIVITIES

SEC. 201. LONG COVID PROGRAMS.

    Title III of the Public Health Service Act (42 U.S.C. 241 et seq.) 
is amended by adding at the end the following:

                    ``PART X--LONG COVID ACTIVITIES

``SEC. 399PP. PUBLIC HEALTH SURVEILLANCE OF LONG COVID AND INFECTION-
              ASSOCIATED CHRONIC CONDITIONS.

    ``(a) In General.--The Secretary, acting through the Director of 
the Centers for Disease Control and Prevention, shall establish or 
continue, as applicable, surveillance activities to better understand 
the burden and severity of Long COVID and related infection-associated 
chronic conditions, with specific consideration given to vulnerable 
populations, such as children. In carrying out this section, the 
Secretary shall--
            ``(1) collect data on the incidence, prevalence, and 
        severity of Long COVID and related infection-associated chronic 
        conditions;
            ``(2) monitor for Long COVID and Long COVID-like 
        conditions, as appropriate, to enable early intervention and 
        identification of factors associated with severity of symptoms;
            ``(3) compile, and make publicly available, in accessible 
        formats, Long COVID data collected under paragraph (1);
            ``(4) develop and disseminate best practices for conducting 
        surveillance for State, local, and Tribal public health 
        officials, and other relevant public health stakeholders;
            ``(5) provide technical assistance to international 
        organizations, as applicable, regarding the monitoring of Long 
        COVID; and
            ``(6) conduct additional surveillance activities, as the 
        Secretary determines appropriate, to better understand the 
        burden and severity of Long COVID.
    ``(b) Authorization of Appropriations.--For purposes of carrying 
out this section, there are authorized to be appropriated $32,000,000 
for each of fiscal years 2025 through 2034.

``SEC. 399PP-1. PUBLIC HEALTH PROGRAMMING.

    ``(a) In General.--The Secretary, acting through the Director of 
the Centers for Disease Control and Prevention, shall make grants to 
State, local, and Tribal health departments for the purpose of carrying 
out activities related to Long COVID.
    ``(b) Use of Funds.--A State, local, or Tribal health department 
that receives a grant under subsection (a) may use funds received 
through such grant to--
            ``(1) provide training on the identification of Long COVID 
        to clinicians, public health experts, and other relevant health 
        care professionals;
            ``(2) link individuals with Long COVID to care, as 
        appropriate and applicable;
            ``(3) support the development and dissemination of public 
        information and educational materials on Long COVID, including 
        materials to address misinformation and disinformation;
            ``(4) support laboratory capacity for screening and 
        diagnosis of Long COVID and associated symptoms; and
            ``(5) build, maintain, and sustain jurisdiction-level 
        infrastructure related to preparedness for post-infectious 
        syndromes.
    ``(c) Authorization of Appropriations.--For purposes of carrying 
out this section, there are authorized to be appropriated $45,000,000 
for each of fiscal years 2025 through 2034.

``SEC. 399PP-2. NATIONAL PUBLIC EDUCATION CAMPAIGN ON LONG COVID.

    ``(a) In General.--The Secretary, acting through the Director of 
the Centers for Disease Control and Prevention, and in collaboration 
with national, State, local, and Tribal public health partners, shall 
develop a public education campaign for patients, families, and 
caregivers to educate and increase awareness about Long COVID in 
children and adults. Such campaign shall include information on--
            ``(1) the signs and symptoms of Long COVID;
            ``(2) how to prevent and seek treatment for Long COVID;
            ``(3) self-management tools and support services; and
            ``(4) other topics, as the Secretary determines 
        appropriate.
    ``(b) Consultation.--In developing materials for the campaign, the 
Secretary shall consult with independent, patient-led organizations or 
advocacy groups representing Long COVID patients and their families and 
other relevant stakeholders.
    ``(c) Accessibility.--The public education campaign under this 
section shall be made available in multiple languages, including 
American Sign Language.
    ``(d) Authorization of Appropriations.--For purposes of carrying 
out this section, there are authorized to be appropriated $21,500,000 
for each of fiscal years 2025 through 2029.

``SEC. 399PP-3. PROVIDER EDUCATION.

    ``(a) In General.--The Secretary shall--
            ``(1) develop and make publicly available best practices 
        for coordinated, multidisciplinary care for individuals with 
        Long COVID;
            ``(2) develop, update, as appropriate, and make publicly 
        available clinical guidance and provider education materials, 
        including for providers working with pediatric populations; and
            ``(3) facilitate provider education on Long COVID signs, 
        symptoms, maintenance, and treatment, including through 
        technology-enabled collaborative learning.
    ``(b) Authorization of Appropriations.--For the purpose of carrying 
out this section, there are authorized to be appropriated $3,000,000 
for each of fiscal years 2025 through 2034.''.

SEC. 202. REHABILITATION RESEARCH AND TRAINING CENTER ON LONG COVID 
              AMONG PEOPLE WITH DISABILITIES.

    (a) In General.--Section 240(b)(2)(C) of the Rehabilitation Act of 
1973 (29 U.S.C. 764(b)(2)(C)) is amended--
            (1) in clause (v), by striking ``; and'' and inserting a 
        semicolon;
            (2) in clause (vi), by striking the period and inserting 
        ``; and''; and
            (3) by adding at the end the following:
                            ``(vii) applied research regarding 
                        evidence-based treatments, services, and 
                        supports for individuals with disabilities with 
                        Long COVID or other infection-associated 
                        chronic conditions.''.
    (b) Authorization of Appropriations.--To carry out the amendment 
made by subsection (b), there are authorized to be appropriated to the 
Director of the National Institute on Disability, Independent Living, 
and Rehabilitation Research, $10,000,000 for the period of fiscal years 
2025 through 2029.

SEC. 203. CLINICAL OUTCOMES ASSESSMENTS.

    (a) In General.--The Secretary of Health and Human Services, acting 
through the Commissioner of Food and Drugs, shall establish or continue 
the development and validation of clinical outcomes assessments to 
support regulatory decision making for drugs, including biological 
products, and devices used to treat Long COVID.
    (b) Authorization of Appropriations.--For purposes of carrying out 
this section, there are authorized to be appropriated $9,000,000 for 
each of fiscal years 2025 through 2034.

SEC. 204. ELECTRONIC REPORTING FORM.

    (a) In General.--The Secretary of Health and Human Services, acting 
through the Commissioner of Food and Drugs, shall establish or continue 
the development, refinement, and maintenance of a Long COVID electronic 
reporting form for patients to identify current treatments and 
treatments under development for Long COVID.
    (b) Authorization of Appropriations.--For purposes of carrying out 
this section, there are authorized to be appropriated $16,600,000 for 
each of fiscal years 2025 through 2034.

SEC. 205. LONG COVID CARE NETWORK.

    (a) In General.--The Secretary of Health and Human Services, acting 
through the Director of the Agency for Healthcare Research and Quality, 
shall develop, or continue to support, multidisciplinary Long COVID 
clinics to provide access to comprehensive, coordinated care for 
individuals with Long COVID, particularly underserved populations that 
are disproportionately impacted by the effects of Long COVID.
    (b) Authorizations of Appropriations.--For purposes of carrying out 
this section, there are authorized to be appropriated $10,000,000 for 
each of fiscal years 2025 through 2034.

SEC. 206. RESEARCH ON LONG COVID BEST PRACTICES.

    (a) In General.--The Secretary of Health and Human Services, in 
coordination with the Director of the Agency for Healthcare Research 
and Quality, shall develop, test, synthesize, and disseminate best 
practices and decision support tools related to the clinical care 
organization, delivery, and integration of clinical and social services 
for Long COVID and other infection-associated chronic conditions.
    (b) Authorization of Appropriations.--For the purposes of carrying 
out this section, there are authorized to be appropriated $10,000,000 
for each of fiscal years 2025 through 2034.
                                 <all>